ES2127190T3 - Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo). - Google Patents

Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo).

Info

Publication number
ES2127190T3
ES2127190T3 ES91115080T ES91115080T ES2127190T3 ES 2127190 T3 ES2127190 T3 ES 2127190T3 ES 91115080 T ES91115080 T ES 91115080T ES 91115080 T ES91115080 T ES 91115080T ES 2127190 T3 ES2127190 T3 ES 2127190T3
Authority
ES
Spain
Prior art keywords
chicken
cnp
biologically active
active peptide
new biologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91115080T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Kenji Kangawa
Naoto Minamino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ES2127190T3 publication Critical patent/ES2127190T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN NUEVO PEPTIDO QUE PRESENTA UNA ACCION NATRIURETICA Y UNA ACTIVIDAD VASODEPRESORA, Y POR TANTO, SE PUEDE APLICAR COMO REACTIVO DE DIAGNOSTICO. EL NUEVO PEPTIDO SE PRODUCE MEDIANTE EL PROCEDIMIENTO DE ENERGIA GENETICA ASI COMO MEDIANTE METODOS DE PURIFICACION DE LOS SESOS DE POLLOS O MEDIANTE SINTESIS QUIMICAS.
ES91115080T 1990-09-07 1991-09-06 Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo). Expired - Lifetime ES2127190T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2238293A JP2977158B2 (ja) 1990-09-07 1990-09-07 トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）

Publications (1)

Publication Number Publication Date
ES2127190T3 true ES2127190T3 (es) 1999-04-16

Family

ID=17028039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91115080T Expired - Lifetime ES2127190T3 (es) 1990-09-07 1991-09-06 Un peptido nuevo biologicamente activo procedente del pollo (cnp-pollo).

Country Status (8)

Country Link
US (1) US5338830A (es)
EP (1) EP0475291B1 (es)
JP (1) JP2977158B2 (es)
AT (1) ATE175210T1 (es)
DE (1) DE69130696T2 (es)
DK (1) DK0475291T3 (es)
ES (1) ES2127190T3 (es)
GR (1) GR3029628T3 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
EP3620530A1 (en) 2004-03-31 2020-03-11 Kazuwa Nakao Composition for increasing body height
WO2005094889A1 (ja) 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
TW201717990A (zh) * 2015-07-31 2017-06-01 Igisu Co Ltd Cnp環狀胜肽及含此環狀胜肽之醫藥品、外用劑及化粧品
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
MX2019011508A (es) 2017-03-31 2019-11-01 Alexion Pharma Inc Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes.
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
JP7820148B2 (ja) 2018-08-10 2026-02-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法
MX2022007114A (es) 2019-12-09 2022-07-11 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos.
MX2023002673A (es) 2020-09-04 2023-05-12 Alexion Pharma Inc Métodos para el tratamiento de trastornos de mineralización ósea.
EP4291224A4 (en) 2021-02-12 2025-01-01 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) * 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides

Also Published As

Publication number Publication date
DK0475291T3 (da) 1999-08-30
GR3029628T3 (en) 1999-06-30
EP0475291A1 (en) 1992-03-18
DE69130696D1 (de) 1999-02-11
DE69130696T2 (de) 1999-06-10
JPH04120094A (ja) 1992-04-21
US5338830A (en) 1994-08-16
JP2977158B2 (ja) 1999-11-10
ATE175210T1 (de) 1999-01-15
EP0475291B1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
ES2127189T3 (es) Peptido nuevo biologicamente activo procedente de una rana (rana-cpn).
DK0475291T3 (da) Fra kylling afledt biologisk aktivt peptid (kylling CNP)
ATE145914T1 (de) Anticonvulsive fructopyranose zyklische sulfate und sulfite
NO953601D0 (no) Nukleinsyre som koder for en tumorreksjonsantigenforlöper
EP0711173A4 (en) INSULATED PEPTIDES THAT MAKE 10 COMPLEXES WITH MHC MULEKÜL HLA-C-KLON AND THEIR USE
DE69306956D1 (de) Katalytische verbrennung von organischen verbindungen
IT1229190B (it) Aumentato recupero di petrolio mediante iniezione ciclica di prodotti chimici fluorurati.
DE68925155D1 (de) Verwendung von Halogenkohlenwasserstofflösungsmittel als Reinigungsmittel
DE59007627D1 (de) Katalysatorkörper und Reaktor für heterogene Reaktionsführung.
ATE152734T1 (de) Bpc-peptide, deren herstellung und verwendung
ES2002053A6 (es) Procedimiento para la obtencion de peptidos inihiobidores de renina que contienen grupos hidroxi.
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
DE69010442D1 (de) Reinigung von 1,1-Dichlor-1-fluorethan.
DE69406214D1 (de) Verfahren zur Reinigung von für den menschlichen Verbrauch bestimmtem Wasser
DE69534470D1 (de) Lgmd- gen kodierend für einer calcium abhängigen protease
FR2657791B1 (fr) Compose chimique contenant des alcalins ou des alcalino-terreux catalyseur en contenant et procede de solvolyse utilisant ledit catalyseur.
ATE173762T1 (de) Klonierung der n-methylhydantoinase
ATE14126T1 (de) Verfahren zur herstellung von 2-acyl1,3,4,6,7,11b-2h-hexahydro-4-pyrazino(2,1a)isochinolinonen und zwischenprodukte.
DE59602774D1 (de) Verfahren zur Herstellung von 3.3.5-Trimethylcyclohexanon
ATE209683T1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
DE59301131D1 (de) Metalle und/oder Oxide enthaltende Katalysatorelemente und Verfahren zum oxidativen Abbau von cyclischen organischen Verbindungen
RO95059A (ro) Procedeu pentru prepararea unor cicloalcancarboxanilide
ES2039312T3 (es) Peptido bacteriocina.
DK0661328T3 (da) Hidtil ukendte epoxid-amin-addukter som hærdere til vandige epoxidsystemer
JPS5411323A (en) Production of linear polyurethane elestomers

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 475291

Country of ref document: ES